Arcturus reports durability data against omicron variants, including ba.5, at six-month timepoint following booster with arct-154 covid-19 vaccine

San diego--(business wire)---- $arct #clinicaltrial--arcturus therapeutics holdings inc. (the “company”, “arcturus”, “arcturus therapeutics”, nasdaq: arct), a global, late-stage clinical messenger rna medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced updated data from its ongoing arct-154 booster clinical trial. the new results demonstrate broad neutralizing antibody response against omicron variants of c
ARCT Ratings Summary
ARCT Quant Ranking